Showing results (11-20 of 58) with videos related to
Sort By:
Pageof 6
Haematologica|October 16, 2012
The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemiaThoralf Lange, Thomas Ernst, Franz X Gruber, et al.Frontiers in Neurology|April 12, 2021
CXCL13 and CXCL9 CSF Levels in Central Nervous System Lymphoma-Diagnostic, Therapeutic, and Prognostic RelevanceIlias Masouris, Kirsi Manz, Markus Pfirrmann, et al.Haematologica|March 8, 2005
The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alphaJoerg Hasford, Markus Pfirrmann, Pat Shepherd, et al.Haematologica|July 18, 2009
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinibThomas Ernst, Franz X Gruber, Oliver Pelz-Ackermann, et al.Journal of Cancer Research and Clinical Oncology|January 14, 2017
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinibMarkus Pfirrmann, Dobromira Evtimova, Susanne Saussele, et al.Blood|May 4, 2011
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS scoreJoerg Hasford, Michele Baccarani, Verena Hoffmann, et al.Oncotarget|March 7, 2018
PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cellsJulia Drube, Thomas Ernst, Markus Pfirrmann, et al.Journal of Cancer Research and Clinical Oncology|June 23, 2014
Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phaseMichael Lauseker, Benjamin Hanfstein, Claudia Haferlach, et al.Journal of Cancer Research and Clinical Oncology|December 3, 2019
Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN)Annamaria Brioli, Kirsi Manz, Markus Pfirrmann, et al.Blood|July 9, 2004
Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study GroupGeorg Lenz, Martin Dreyling, Eva Schiegnitz, et al.Pageof 6